ADDF Launches New Phase of $150 Million Diagnostics Accelerator Initiative to Power Next Generation of Alzheimer's Precision Medicine Worldwide
Published: 06 Apr 2026
Author: Towards Healthcare
The Alzheimer's Drug Discovery Foundation announced the launch of the third phase of its Diagnostics Accelerator, backed by an additional $50 million in funding, bringing the initiative's total to $150 million. It showed a transformative impact in blood-based diagnostics. Diagnostics Accelerator will advance the next generation of speed in drug development, enabling combination therapies in a new era of precision medicine for Alzheimer's patients.
Collaboration with initial funders ADDF Co-Founder Leonard A. Lauder and Bill Gates, the Diagnostics Accelerator was founded on the belief that the path to effective Alzheimer's treatments begins with better diagnostics.
The market is driven by the increasing prevalence of Alzheimer's disease.
According to Towards Healthcare, the Blood-based biomarker for Alzheimer’s disease diagnostics market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 198.72 million in 2026 to approximately USD 841.9 million by 2035, representing a compound annual growth rate (CAGR) of 17.4% from 2026 to 2035. Growth is driven by an increasing global population, leading to a higher incidence of Alzheimer's disease, along with demand to detect early diagnoses towards developing a technology platform and enhancing the sensitivity, specificity, and affordability of blood-based biomarker tests.
From Amyloid to a Broader Biomarker Landscape
In 2025, Fujirebio received the first-ever Food and Drug Administration (FDA) approval for an Alzheimer’s blood test and agreed with Alamar Biosciences to advance its ultra-sensitive NULISA platform, which enablesthe detection of a broad range of blood-based biomarkers. According to the ADDF blood test offers the opportunity to replace more invasive and costly diagnostic tools, such as PET scans and spinal taps, with clinical diagnosis and clinical trial enrollment.
Executive Vice President, Global Product Strategy & Commercialisation at Biogen and ADDF Board Member Rachid Izzar said Changing the trajectory of Alzheimer's disease will require earlier detection and intervention, and that progress depends on therapeutic and diagnostic innovation advancing together.
Biogen is continuing to support the Alzheimer's Drug Discovery Foundation Diagnostics Accelerator through DxA 3.0 to accelerate research and development that will support earlier detection, faster clinical decision-making, and more personalised treatment strategies that will ultimately help give people living with Alzheimer's disease and their families more time and better options.
A recent report by Towards Healthcare highlights that the Blood-based biomarker for Alzheimer’s disease diagnostics market is witnessing dominance of clinical laboratories and hospital labs, which hold the largest revenue by increasing use of immunoassay and the need for more sensitive and specific tests to improve diagnostic accuracy and patient accuracy.